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Abstract
Background: Multiple sclerosis (MS) is a frequent and
often severe autoimmune disease of the central nerv-
ous system. We describe a newly developed enzyme-
linked immunosorbent assay (ELISA)-based test
system for the assessment of neuronal autoantibod-
ies in serum and cerebrospinal fluid (CSF). This tool
could help define autoimmune status and thus be a
potential means of therapeutic surveillance.
Methods: We used an assay system (ELISA, E100,
Mediagnost) based on purified bovine antigens
wmyelin-oligodendrocyte glycoprotein (MOG), myelin
basic protein (MBP), myelin-associated glycoprotein
(MAG), proteolipid protein (PLP) and alpha-B-crystal-
line (CRY) antibodies for the measurement of specific
immunoglobulin G (IgG) and immunoglobulin M
(IgM) antibodies. Assay characteristics and prelim-
inary validation were conducted by measurement of
serum and CSF samples from 41 MS patients and 128
patients with other neurological diseases (OND).
Results: We measured the inter- (17.8/10.1%) and
intra-assay variability (5.5/6.7%); linearity (1:250–
1:16,000), and specificity of IgG and IgM. We dem-
onstrate that by the results of this test system MS
patients can be differentiated from patients with OND.
Conclusions: The ELISA kit we evaluated is suitable
for the measurement of neuronal autoantibodies. The
initial validation demonstrates its potential use in the
differential diagnosis of central neuronal system
diseases.
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Introduction
T-cell mediated autoimmunity is a hallmark of the
pathogenesis of multiple sclerosis (MS) (1, 2). Possi-
bly, autoreactive CD4q T-cells, activated by an exter-
nal stimulus, such as viral infections, initiate the
demyelinating process (1). The relevance of B-cells
has long been questioned because myelin-specific
antibodies are not able to induce MS in animal mod-
els. But the presence of autochthonously synthesised
antibodies in the cerebrospinal fluid (CSF) of MS
patients is well known, and detection of oligoclonal
bands is of diagnostic importance (3–5). Therefore, it
is assumed that the degree of central nervous tissue
injury is influenced by the amount of antibodies (6).
Thus, B-cells in addition to T-cells, may take part in
tissue damage in MS. Recently, the relevance of B-
cells in MS pathology has been proven by new ther-
apeutic strategies, such as the use of monoclonal
antibodies (e.g., rituximab) that target B-cells and
eliminate them from the circulation. In clinical studies,
MS patients treated with rituximab had significantly
less inflammatory brain lesions and less clinical
relapses compared to the control group treated with
placebo (7, 8). As a result, antibody producing B-cells
are now the focus of MS research.
The increase in CSF antibody concentrations is
caused by clonal, B-cell driven intrathecal antibody
synthesis (9). However, this is not specific for MS.
Several studies have investigated the diagnostic
value of autoantibodies against myelin proteins by
Western blot, enzyme-linked immunosorbent assay
(ELISA) or flow cytometry (10), employing recombi-
nant, natural purified or peptide antigens. The results
are somewhat contradictory. Some studies show the
relevance of antibodies against myelin basic protein
(MBP), while others do not (11, 12). Similarly incon-
sistent results have been obtained for myelin proteo-
lipid protein (PLP), myelin-associated glycoprotein
(MAG), and myelin oligodendrocyte glycoprotein
(MOG) (12–17). These contradictory results may par-
tially be explained by differences in methodologies.
In addition, measurement of only one or two auto-
antibody titres may not be sufficient for diagnostic
purposes.
The present study shows data on the first test sys-
tem using a combination of purified bovine MAG,
MBP, MOG, PLP and alpha-B-crystalline (CRY) as anti-
genic materials. These five antigens were included in
order to facilitate the direct and simultaneous com-
parison of reactions against autoantigens in MS and
other neurological diseases (OND).
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In the present study, we focus on the technical
evaluation of immunoglobulin G (IgG) and immuno-
globulin (IgM) measurements. We present data on
reproducibility, sensitivity, linearity, and interference.
Also, we investigated a small group of MS patients
with corresponding serum and CSF samples and
compared these to patients with non-MS neurological
diseases.
Materials and methods
Chemical reagents were purchased from Merck (Darmstadt,
Germany) or Sigma-Aldrich (Munich, Germany).
Patients
The diagnosis of MS was defined clinically and supported by
laboratory data according to the internationally accepted
McDonald criteria (18). Only MS patients with a chronic pro-
gressive form of MS and without signs of any OND were
included. Forty-one patients with MS met the inclusion cri-
teria. Of these, 36 showed secondary progressive disease
course, while five patients were progressive from the onset.
We also included 128 patients with OND as the control
group. The following diseases were present in the control
group (patient numbers are given in brackets): spinal canal
stenosis (ns7), idiopathic facial nerve paresis (ns8), cere-
bral inflammation (ns46) ischaemic stroke (ns12), vascular
dementia (ns11), various types of polyneuropathies (ns20)
and further OND (ns24). Patients with suspicion or evidence
of MS were excluded from the OND group.
Serum and CSF samples
CSF and serum samples were obtained from the routine
laboratory of the Neurologische Klinik and Poliklinik of the
Martin-Luther-Universita¨t Halle-Wittenberg and from Neuro-
logische Klinik of Krankenhaus Martha-Maria Halle-Do¨lau.
Paired CSF and serum specimens were obtained from each
patient and stored frozen at –208C until use, within
24 months. The CSF and serum samples had been used for
routine diagnosis. Albumin, total IgG and IgM content were
quantitated using standard immunochemical nephelometry.
Ethics
The study was performed in accordance with the
Declaration of Helsinki Ethical Guidelines and was approved
by the Ethics Committee of the Martin-Luther University
Halle-Wittenberg, Germany.
ELISA
The ELISA (E100) for the detection of neuronal autoantibod-
ies was developed by Mediagnost, Germany using a serum
internal standard pool for calculation of antibody titres and
employing microplates coated with purified bovine MAG,
MOG, MBP, PLP and CRY. The assay was conducted accord-
ing to the manufacturer’s instructions (Mediagnost, Reutling-
en Germany). Briefly, 100 mL of diluted serum or CSF was
pipetted into each well of the microtitre plate and incubated
under agitation at 350 rpm for 2 h at room temperature. The
biotinylated detection antibody and horseradish-peroxidase
streptavidin-conjugate were added sequentially. Each was
incubated for 60 min at room temperature. After the addition
of substrate and stop solution, the optical density was meas-
ured at 450 nm. The arbitrary antibody amounts were cal-
culated using extinctions of a standard serum included in the
testkit.
Data transformation and index calculation
Specific antibody content was measured for 41 paired serum
and CSF samples of MS patients and 128 paired samples of
OND patients. Additionally, total IgG and IgM content were
determined in serum and CSF by routine methods. For sta-
tistical analysis, the relative amount of specific IgG and IgM
antibody was calculated for each antigen in serum and CSF
separately according to the following formula:
sA–Ig
srelative ØsA–Ig
tIg
sA–Ig, antigen-specific IgG or IgM antibody concentration
in CSF or serum; tIg, total IgG or IgM antibody concentration
wg/Lx in CSF or serum.
In a second step, the quotient of specific IgG/IgM in CSF
and serum was calculated for each antigen separately:
CSF Serum –1w z w zsA–Ig sA–Ig
x | x |= ssA–Index
y ~ y ~tIg tIg
Statistical analysis
All statistical analyses were conducted by using SPSS for
Windows Version 11.0.0 (2001, Chicago, IL, USA). Beside
descriptive statistics for calculation of the mean and stan-
dard deviation (SD) for each antigen (Table 2), the main
focus was the analysis of differences between the CSF-
serum quotients in two groups, the MS patients and the OND
patients. Significance level was set to as0.05. Tested
hypothesis (H0) was:
1. no differences between the specific antibody content of
serum and CSF in patients with MS or OND could be
detected, and
2. no difference between the specific antibody index of
patients with MS or OND could be detected.
Analysis of variance was used to detect significant differ-
ences between the mean of the two groups for specific IgG
and IgM in serum and CSF antigen as well as for the IgG
and IgM sA-Index.
Results
Precision and reproducibility
The characteristics of the applied assay are shown in
Table 1. Inter-assay variability was tested by doing at
least five measurements of three different serum
samples on different occasions. On average the mean
relative coefficients of variation (CV) for inter-assay
variance of IgG and IgM antibody titres against MOG,
MBP, MAG, PLP and CRY were 12% (SD 4.7) and 14%
(SD 1.5), respectively. To assess the intra-assay vari-
ance, serum samples were measured at least 6 times
in the same assay. The resulting CVs in the case of
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Table 1 Precision and reproducibility.
MOG MBP MAG PLP CRY
Inter-assay IgG mean, %CV 13.77 7.17 10.75 17.47 9.30
SD inter-assay IgG SD 6.61 1.94 6.70 3.84 4.17
Inter-assay IgM mean, %CV 14.84 12.74 14.07 15.64 14.14
SD inter-assay IgM SD 2.87 6.36 3.11 4.19 2.85
Intra-assay IgG Mean, %CV 3.94 3.76 7.43 8.42 3.73
SD intra-assay IgG SD 1.83 1.49 3.20 5.82 0.66
Intra-assay IgM mean, %CV 4.66 3.95 11.35 6.31 5.43
Intra-assay IgM SD 2.59 2.58 2.93 2.92 3.81
Inter-assay variability was tested by doing five measurements of three different serum samples and for intra-assay variance,
serum samples were measured 6 times in the same assay. The mean %CV and SD of the three samples is shown here.
Figure 1 Linearity of sample dilution of a representative
sample.
The arbitrary optical densities for each dilution of IgM (A)
and IgG (B) are shown. Data were analysed by linear regres-
sion, resulting equations and correlation factors are shown.
IgG and IgM measurements were on average 5.5%
(SD 2.0) and 6.6% (SD 2.3), respectively.
Analytical sensitivity and accuracy
For investigation of analytical sensitivity, we meas-
ured 14 zero samples (blank) and thus calculated
mean and SD. The analytical sensitivities, defined as
the mean antibody titre of the zero sampleq3 SD,
were 0.3, 0.48, 0.21, 0.11 and 0.61 arbitrary titre units
for IgG measurement and 1.68, 0.54, 0.34, 2.4, 0.76 in
the case of IgM for MOG, MBP, MAG, PLP and CRY,
respectively.
Linearity is shown in a representative specimen in
Figure 1. An exemplary serum sample was diluted
from 1:1000 up to 1:16,000 (IgG) and 1:250 up to
1:3000 (IgM). In Figure 1, the resulting optical densi-
ties of each dilution are shown and analysed by linear
regression analysis, demonstrating a high degree of
linearity.
Interference
Interference and cross-reactivity of the assay were
tested by either adding triglycerides (Institute for Ref-
erence Materials and Measurements, Geel, Belgium)
or bilirubin (Sigma-Aldrich, Munich, Germany) in
various concentrations to a serum sample. Neither
bilirubin (up to 200 mg/L; 0.342 mmol/L) nor triglyc-
erides (up to 200 g/L) interfered significantly with the
measurement of MOG, MAG and CRY antibody titres.
Determination of MBP antibody titre was significantly
influenced by both substances, in the case of PLP the
measurement of IgM antibodies was also influenced
by triglycerides as well as by bilirubin.
Specificity
Specificity of bound antibodies was investigated by
the use of soluble antigen for competitive binding.
Results are shown in Figure 2. The addition of control
material, bovine serum albumin (BSA), did not result
in significant reduction of antibody binding. In the
case of MOG, MAG, and CRY addition of antigenic
material resulted in a concentration dependent reduc-
tion of IgG and IgM binding. Antibody binding to MBP
and PLP could not be inhibited by incubation of the
sample with antigen.
Preliminary validation
Exemplarily, the capability of the described assay to
discriminate between MS and OND was investigated.
Assuming that each kind of antibody is produced by
a pool of different B-cells, the measured values were
seen as independent results. Furthermore, each
patient sample can be regarded as a source of inde-
pendent antibody titre values. Thus, an analysis of
variance was used to evaluate whether significant
differences between the means of each group exist.
Significant differences (p-values in parentheses) were
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Figure 2 Binding competition by preincubation with anti-
gen material.
Samples were diluted (1:500) in dilution buffer containing
indicated concentrations of protein. Shown is the relative
binding of IgM (A) and IgG (B) antibodies in comparison to
negative control.
detected for the anti-MAG-IgG in serum (0.028) and
anti-MAG IgM in CSF (0.045), only. Additionally, for
two sA-Indices, a significant difference between the
two groups was detected: IgG-PLP (0.008) and IgM-
PLP (0.04). Detailed ANOVA results obtained for the
amount of specific antibody as well as for the
specific antibody indices (CSF/serum) are shown in
Table 2A and 2B.
Discussion
Beside T-cell mediated neuronal destruction, also B-
cells and B-cell produced antibodies seem to be of
functional relevance in the pathogenesis of MS (19).
Therefore, an assay system for the detection of spe-
cific anti-myelin IgG or IgM antibodies may be of use
to study abnormalities of the humoral immune regu-
lation in MS. The assay that is characterised here
employs bovine MOG, MAG, MBP, PLP and CRY as
antigenic materials for the simultaneous detection of
antibodies against all these antigens. Thus, we
assume that a reliable multidimensional test in con-
nection with statistical analysis will be able to detect
small changes in the immune status of the patient.
This may be of relevance for understanding the
pathogenesis of this inflammatory CNS disease. Fur-
thermore, myelin autoantibody detection may be use-
ful to monitor the dynamics of neuro-inflammation
and thus may eventually be of therapeutic relevance.
Precision and reproducibility of the ELISA-based
commercial assay detecting five specific neuronal
autoantibodies in human serum and CSF revealed on
average for IgG 5.5% and 11.7%, and IgM 6.3% and
14.3%. These values are within an acceptable range
for immunoassays measuring autoantibodies (20, 21).
Furthermore, sensitivity and linearity (Figure 1) are
excellent. Bilirubin and triglycerides interfere in MBP
and PLP measurements. Thus, lipaemic or icteric
samples cannot be used for this assay.
Further, the specificity of the assay system was test-
ed by antigen competition. The control (BSA) does
not influence the binding of IgG antibodies, but a pre-
incubation of the diluted sample together with anti-
gen results in a concentration dependent decrease of
antibody binding. Only in the case of MBP and PLP
such a concentration dependent decrease could not
be shown. Here, even an increase in antibody binding
was detected (Figure 2). Analysis of amino acid
sequence of PLP and MBP reveals that in comparison
to MOG, MAG, and CRY, PLP contains four transmem-
brane domains, more than the other proteins (22, 23).
MBP is a soluble, membrane-associated protein but it
is well known that the protein is able to interact with
itself and with other proteins (24, 25). Thus, we
assume that the limited success in competition of
antibody binding eventually does not reflect non-spe-
cific binding but rather results from biochemical prop-
erties of the antigen.
The preliminary clinical validation demonstrates
that patients with MS can be differentiated from
patients with OND. The distinction was based on the
measured amount of antibodies against a single anti-
gen present in serum and/or CSF. Although only a rel-
atively small group of MS patients with primary or
secondary progressive MS was included into the
study, this assay seems to be a suitable tool for dis-
criminating between MS and OND on the basis of
autoantibodies in serum and CSF. Contradictory to
current pathogenetic concepts of MS, the CSF/serum
specific antibody index (sA-Index) against myelin anti-
gens was found to be significantly decreased in MS
patients compared to patients with OND, if a signifi-
cant difference has been detected at all. This is also
reflected in the amount of MAG-specific antibody in
serum and CSF. MS patients have significantly more
anti-MAG antibodies in serum but less in CSF com-
pared with OND patients. One possible reason for this
result may be the presence of patients with inflam-
matory diseases, such as meningitis in the OND
group. Furthermore, in neurodegeneration such as
stroke or vascular dementia, secondary autoimmune
phenomena might be of pathogenetic relevance. Rea-
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Table 2A Statistics.
MS patients n Mean SD OND patients n Mean SD
Serum
IgG MBP 41 0.092 0.05 IgG MBP 127 0.095 0.11
IgG MOG 41 0.106 0.06 IgG MOG 128 0.109 0.07
IgG CRY 41 0.106 0.06 IgG CRY 128 0.101 0.04
IgG MAG 41 0.093 0.05 IgG MAG 128 0.072 0.05
IgG PLP 41 0.066 0.03 IgG PLP 128 0.064 0.07
IgM MBP 41 1.548 0.88 IgM MBP 128 1.509 1.45
IgM MOG 41 1.797 1.19 IgM MOG 128 1.993 2.72
IgM CRY 41 1.912 1.15 IgM CRY 128 1.783 2.00
IgM MAG 41 0.498 0.34 IgM MAG 128 0.541 0.70
IgM PLP 41 0.339 0.3 IgM PLP 128 0.38 0.75
Cerebrospinal fluid
IgG MBP 41 37.44 23.09 IgG MBP 128 29.3 25.56
IgG MOG 41 4.31 5.31 IgG MOG 128 4.70 8.11
IgG CRY 41 7.33 4.4 IgG CRY 128 7.42 10.23
IgG MAG 41 3.46 2.82 IgG MAG 128 4.01 9.70
IgG PLP 41 2.88 2.83 IgG PLP 128 5.57 15.63
IgM MBP 41 1499 1460 IgM MBP 128 1079 1367
IgM MOG 41 38.23 155.25 IgM MOG 128 120.4 374.0
IgM CRY 41 67.78 102.46 IgM CRY 122 125.98 242.15
IgM MAG 41 16.69 25.32 IgM MAG 128 74.47 170.18
IgM PLP 41 29.85 36.02 IgM PLP 128 124.71 448.8
Relative amount of antigen-specific IgG and IgM of multiple sclerosis patients (MS) and patients with other neurological
diseases (OND). Significant difference between both groups is shown by bold italic letters.
Table 2B Statistics.
MS patients n Mean SD OND patients n Mean SD
IgG MBP 40 752 1731 IgG MBP 120 669 1450
IgG MOG 41 49 70 IgG MOG 121 47 56
IgG CRY 41 79 45 IgG CRY 122 81 112
IgG MAG 41 36 23 IgG MAG 117 53 57
IgG PLP 40 42 33 IgG PLP 115 76 78
IgM MBP 41 1068 897 IgM MBP 122 1994 11,115
IgM MOG 41 24 96 IgM MOG 122 103 360
IgM CRY 41 49 76 IgM CRY 122 102 240
IgM MAG 41 49 92 IgM MAG 121 155 340
IgM PLP 41 127 183 IgM PLP 113 369 723
IgG SUM 41 937 1717 IgG SUM 128 1018 2132
IgM SUM 41 1317 970 IgM SUM 128 2774 11,681
IgG and IgM sA-Index (CSF/serum) of multiple sclerosis patients (MS) and patients with other neurological diseases (OND).
The indices that differ significantly between both groups are marked by bold italic letters.
sons for a decreased sA-Index in MS may, however,
also concern the selection of MS patients. Thus, in
secondary progressive MS, inflammation may be less
prominent than in cases with a relapsing-remitting
type of course. Furthermore, in cases with a progres-
sive course from onset, neuro-inflammation may be
even less prominent than in patients with secondary
progression. Actually, only cases with progressive
types of MS course were included into the present
investigation, a fact that may partially account for the
obtained result.
We finally conclude that the commercial Media-
gnost ELISA E100 is a reliable assay for the measure-
ment of human antibodies against MOG, MBP, MAG,
PLP and CRY. The assay may be especially suited for
the investigation of anti-myelin autoimmune re-
sponses in primary inflammatory diseases of the cen-
tral nervous system, such as MS. However, it might
also give worthful information on secondary antimye-
lin autoimmune responses in primary degenerative
diseases of the central nervous system, such as e.g.,
Alzheimer’s disease or motor neuron disorders.
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